1-10 of 10
Devalingam Mahalingam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L. Coveler, Steven Powell, Bruno Bastos, Elizabeth Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor Weisskittel, Hu Li, Brittany A. Borden, R. Donald Harvey, Solmaz Sahebjam, Andrés Cervantes, Austin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 522–531.
https://doi.org/10.1158/1078-0432.CCR-23-1916
Published: 01 February 2024
View article titled, Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Open the PDF for Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Lipika Goyal, Cynthia Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6158–6167.
https://doi.org/10.1158/1078-0432.CCR-20-1310
Published: 01 December 2020
View article titled, Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Open the PDF for Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Devalingam Mahalingam, Grey A. Wilkinson, Kevin H. Eng, Paul Fields, Patrick Raber, Jennifer L. Moseley, Karol Cheetham, Matt Coffey, Gerard Nuovo, Pawel Kalinski, Bin Zhang, Sukeshi Patel Arora, Christos Fountzilas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 71–81.
https://doi.org/10.1158/1078-0432.CCR-19-2078
Published: 03 January 2020
View article titled, Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Open the PDF for Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Devalingam Mahalingam, Judy S. Wang, Erika P. Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall Schreeder, H. Jeffrey Wilkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (12): 3508–3516.
https://doi.org/10.1158/1078-0432.CCR-18-3185
Published: 14 June 2019
View article titled, Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Open the PDF for Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John S. Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison J. Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 847–857.
https://doi.org/10.1158/1078-0432.CCR-15-1338
Published: 14 February 2016
View article titled, Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Fabian Birzele, Edgar Voss, Adam Nopora, Konrad Honold, Florian Heil, Sabine Lohmann, Henk Verheul, Christophe Le Tourneau, Jean-Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valerie Meresse, Stefan Weigand, Valeria Runza, Michael Cannarile
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (12): 2753–2762.
https://doi.org/10.1158/1078-0432.CCR-14-2141
Published: 14 June 2015
View article titled, CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Open the PDF for CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients in another window
Includes: Supplementary data
Journal Articles

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Jordi Rodon, Hussein A. Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, Jose Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine L. Rose, Dereck D. Amakye, Reinhard Dummer, Alain C. Mita
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1900–1909.
https://doi.org/10.1158/1078-0432.CCR-13-1710
Published: 31 March 2014
View article titled, A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Open the PDF for A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, Shaunita A. Michael, Alain C. Mita, Monica M. Mita, Marilyn Mulay, Poornima Shubhakar, Min Zhu, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3414–3427.
https://doi.org/10.1158/1078-0432.CCR-11-3369
Published: 14 June 2012
View article titled, Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors
Open the PDF for Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Devalingam Mahalingam, Ernest C. Medina, Juan A. Esquivel, II, Claudia M. Espitia, Sabrina Smith, Kelli Oberheu, Ronan Swords, Kevin R. Kelly, Monica M. Mita, Alain C. Mita, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 141–153.
https://doi.org/10.1158/1078-0432.CCR-09-1385
Published: 04 January 2010
View article titled, Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Open the PDF for Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels in another window
Journal Articles

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Evelien W. Duiker, Elisabeth G.E. de Vries, Devalingam Mahalingam, Gert Jan Meersma, Wytske Boersma-van Ek, Harry Hollema, Marjolijn N. Lub-de Hooge, Go M. van Dam, Robbert H. Cool, Wim J. Quax, Afshin Samali, Ate G.J. van der Zee, Steven de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2048–2057.
https://doi.org/10.1158/1078-0432.CCR-08-1535
Published: 16 March 2009
View article titled, Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
Open the PDF for Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model in another window
Includes: Supplementary data